Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1105 participants.

Also called NCT06858878

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,105 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06858878
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Bulgaria, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, South Korea, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06858878. Randomized; double masking; primary purpose treatment. Start 2025-03-17 (actual); primary completion 2027-01-21 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Acronym
MARITIME-2
Condition
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Intervention (Drug)
Maridebart cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct06858878
Content hash
1b06844129c4a30057249668782dc5173dcb3569805e6e65dd5acb394c69fa2d